Danaher Q2 Earnings Beat, Raises Full-Year EPS Guidance
DHR is trading near its 52-week low of $160.93 (15% above the low).
Summary
Danaher reported Q2 2026 earnings above expectations, with net earnings up 60% to $870 million and adjusted EPS of $1.94. The company raised its full-year adjusted EPS guidance and provided a positive outlook, driven by improving end markets and strong bioprocessing orders.
Key Events · Earnings and Guidance · DHR
-
Q2 Earnings Beat
Net earnings of $870 million ($1.23 diluted EPS), up 60% year-over-year. Non-GAAP adjusted diluted EPS of $1.94, up 8.0%.
-
Revenue Growth Accelerates
Revenue of $6.3 billion, up 5.5% year-over-year. Core revenue growth of 3.0%, with Life Sciences delivering its strongest quarter in several years.
-
Full-Year EPS Guidance Raised
Adjusted diluted EPS guidance increased to $8.45–$8.60 from $8.35–$8.55, reflecting confidence in continued recovery and Masimo integration.
-
Bioprocessing Orders Surge
Bioprocessing orders grew mid-teens in Q2, indicating strong underlying demand despite near-term customer project timing headwinds.
Analysis · DHR · Industrial Applications And Services
Danaher delivered a strong Q2, with net earnings surging 60% to $870 million and adjusted EPS of $1.94 beating expectations. Core revenue grew 3%, driven by a rebound in Life Sciences and mid-teens bioprocessing order growth. Management raised full-year adjusted EPS guidance to $8.45–$8.60, signaling confidence in sustained momentum. The pending StatLab acquisition adds a high-growth, recurring-revenue asset to the diagnostics portfolio. Against a backdrop of recent debt-fueled M&A, these results demonstrate effective integration and operational execution, supporting the premium valuation.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DHR was trading at $184.65 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $142.3B. The 52-week trading range was $160.93 to $242.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.